Цитарабин

Основна информация

  • Търговско наименование:
  • Цитарабин Стада 50 mg/ml разтвор за инжекции/инфузии - 20ml; 80ml x 1
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Цитарабин Стада 50 mg/ml разтвор за инжекции/инфузии - 20ml; 80ml x 1
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Cytarabine Stada, 50 mg/ml solution for injection/infusion - 20ml; 80ml x 1

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20020852
  • Дата Оторизация:
  • 14-08-2014
  • Последна актуализация:
  • 01-06-2018

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

27-8-2018

Vyxeos (Jazz Pharmaceuticals Ireland Ltd)

Vyxeos (Jazz Pharmaceuticals Ireland Ltd)

Vyxeos (Active substance: daunorubicin / cytarabine) - Centralised - Authorisation - Commission Decision (2018)5695 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4282

Europe -DG Health and Food Safety

10-7-2018

DepoCyte (Pacira Limited)

DepoCyte (Pacira Limited)

DepoCyte (Active substance: Cytarabine) - Centralised - Withdrawal - Commission Decision (2018)4490 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety